epidermal-growth-factor and Pericardial-Effusion

epidermal-growth-factor has been researched along with Pericardial-Effusion* in 1 studies

Other Studies

1 other study(ies) available for epidermal-growth-factor and Pericardial-Effusion

Article	Year
Response to gefitinib in pericardial effusion due to lung cancer. Acta medica (Hradec Kralove), 2003, Volume: 46, Issue:4 We described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatment with gefitinib for female patients with pericarditis carcinomatosa due to lung adenocarcinoma, even if they have a poor performance status and are not indicated for other intensive therapy. Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Pericardial Effusion; Protein-Tyrosine Kinases; Quinazolines	2003

Article

Year

Response to gefitinib in pericardial effusion due to lung cancer.

Acta medica (Hradec Kralove), 2003, Volume: 46, Issue:4

We described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatment with gefitinib for female patients with pericarditis carcinomatosa due to lung adenocarcinoma, even if they have a poor performance status and are not indicated for other intensive therapy.

Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Pericardial Effusion; Protein-Tyrosine Kinases; Quinazolines

2003